Clinical Trial Update: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of NNC0114-0006 in active Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• NNC0114-0006

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Crohn's Disease | Phase 2 | Status: COMPLETED